BR9905305A - Stable formulations in apomorphine solution - Google Patents

Stable formulations in apomorphine solution

Info

Publication number
BR9905305A
BR9905305A BR9905305-5A BR9905305A BR9905305A BR 9905305 A BR9905305 A BR 9905305A BR 9905305 A BR9905305 A BR 9905305A BR 9905305 A BR9905305 A BR 9905305A
Authority
BR
Brazil
Prior art keywords
solution
stable formulations
apomorphine
apomorphine solution
stable
Prior art date
Application number
BR9905305-5A
Other languages
Portuguese (pt)
Inventor
Eva Bernini
Gaetano Brambilla
Paolo Chiesi
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of BR9905305A publication Critical patent/BR9905305A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<B>"FORMULAçõES ESTáVEIS EM SOLUçãO DE APOMORFINA"<D> Uma formulação contendo hemiidrato de cloridrato de apomorfina em uma solução aquosa, em combinação com excipientes, sendo que esta solução se mantém estável por, pelo menos, dois anos, a uma temperatura de até 25° C, e capaz de garantir uma contagem microbiana baixa após o frasco ter sido aberto e durante o uso do medicamento.<B> "STABLE FORMULATIONS IN APOMORPHINE SOLUTION" <D> A formulation containing apomorphine hydrochloride hemihydrate in an aqueous solution, in combination with excipients, this solution remaining stable for at least two years at a temperature up to 25 ° C, and able to guarantee a low microbial count after the bottle has been opened and while using the drug.

BR9905305-5A 1998-10-30 1999-10-29 Stable formulations in apomorphine solution BR9905305A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998MI002331A IT1303684B1 (en) 1998-10-30 1998-10-30 FORMULATIONS OF APOMORPHINE IN SOLUTION STABLE OVER TIME.

Publications (1)

Publication Number Publication Date
BR9905305A true BR9905305A (en) 2001-03-20

Family

ID=11380970

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9905305-5A BR9905305A (en) 1998-10-30 1999-10-29 Stable formulations in apomorphine solution

Country Status (6)

Country Link
BR (1) BR9905305A (en)
ES (1) ES2156763B1 (en)
FR (1) FR2785188B1 (en)
GB (1) GB2343376B (en)
GR (1) GR990100373A (en)
IT (1) IT1303684B1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770376B2 (en) * 1999-09-29 2004-02-19 Procter & Gamble Company, The Compositions having improved stability
TW200526268A (en) * 2003-12-17 2005-08-16 Takeda Pharmaceutical Injectable composition
TW201035054A (en) * 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
CN107693486A (en) 2012-06-05 2018-02-16 纽罗德姆有限公司 Composition comprising apomorphine and organic acid and application thereof
WO2015157212A1 (en) * 2014-04-10 2015-10-15 Us Worldmeds, Llc Stable apomorphine composition and uses thereof

Also Published As

Publication number Publication date
FR2785188A1 (en) 2000-05-05
GB9925602D0 (en) 1999-12-29
ES2156763B1 (en) 2002-03-01
GB2343376B (en) 2003-12-31
ITMI982331A1 (en) 2000-04-30
FR2785188B1 (en) 2004-10-29
GR990100373A (en) 2000-06-30
ES2156763A1 (en) 2001-07-01
GB2343376A (en) 2000-05-10
IT1303684B1 (en) 2001-02-23

Similar Documents

Publication Publication Date Title
PE20010053A1 (en) AMOXICILLIN AND POTASSIUM CLAVULANATE FORMULATION
MC2051A1 (en) NEW CONDENSED HETEROCYCLIC COMPOUNDS
CO5261563A1 (en) PHARMACEUTICAL COMPOSITIONS THAT PROVIDE POWERFUL FARMACO CONCENTRATIONS
BR0113643A (en) Guanidinobenzamides compounds as mc4-r agonists and their uses
BR9911579A (en) Use of an antimicrobial compound for disinfection
ES2188945T3 (en) IMPROVEMENTS IN OR RELATED TO COMPOSITIONS CONTAINING CREATINE.
BR0101332A (en) Topical ophthalmic formulation in the form of an aqueous solution, and, using a cyclosporine in combination with hyaluronic acid or one of its salts and with polysorbate 80
ES2097297T3 (en) ISOQUINOLEIN-5-IL-SULFONAMIDES, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ES2111547T3 (en) PROLONGED RELEASE TABLET.
BR0209206A (en) Azithromycin hydrate clathrate with 1,2-propylene glycol, a process for its preparation and a pharmaceutical composition comprising the same
ES2108129T3 (en) NEW DERIVATIVES OF PIRAZINE, ITS PREPARATION AND USE.
AP2003002716A0 (en) Medicinal compositions containing propenone derivatives.
DK324185A (en) 2-SUBSTITUTED 1,3-PROPYLIDENDIPHOSPHONATE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS WITH CONTENTS
NZ505821A (en) Pharmaceutical compositions of uridine triphosphate
ATE267601T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PEMETREXED TOGETHER WITH MONOTHIOGLYCEROL, L-CYSTEINE OR THIOGLYCOLIC ACID
BR9905305A (en) Stable formulations in apomorphine solution
BR0314000A (en) Supporting device in particular for a fermentation apparatus
BR0208169A (en) Chemical Compounds
BR9915692A (en) Eletriptan hydrobromide monohydrate
ATE257481T1 (en) MACROLIDS
ES2193007T1 (en) STABLE PHARMACEUTICAL FORMULATION THAT INCLUDES MODIFICATION II OF TORSEMIDA.
AR031010A1 (en) A PHARMACEUTICAL COMPOSITION, USEFUL TO INHIBIT THE CELL DANE
DK351982A (en) PROCEDURE FOR THE PREPARATION OF AMINOGLYCOSIDE DERIVATIVES
BR0214487A (en) A pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for the treatment of diabetes.
BR9915835A (en) Pharmaceutical composition, and, process for the preparation of a composition

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired